Literature DB >> 22787287

8-(3-Isothiocyanatostyryl)caffeine Is a Selective, Irreversible Inhibitor of Striatal A(2)-Adenosine Receptors.

Xiao-Duo Ji1, Carola Gallo-Rodriguez, Kenneth A Jacobson.   

Abstract

8-(3-Isothiocyanatostyryl)caffeine (ISC) was synthesized and shown to inhibit selectively the binding of [(3)H]CGS 21680 (an A(2a)-selective agonist) at adenosine receptors in striatal membranes. The K(i) value at A(2a)-receptors was found to be 110 nM (rat), with selectivity ratios for A(2a) versus A(1)-receptors in rat, guinea pig, bovine, and rabbit striatum of >100-fold. Preincubation of membranes with ISC caused a dose-dependent, irreversible antagonism of the binding of [(3)H]CGS 21680, with an IC(50) value of 3 μM. The irreversibility is likely due to the presence of the chemically reactive isothiocyanate group, since the binding of the corresponding analogue in which the isothiocyanate was replaced with a chloro group was completely reversible. The potency of ISC to irreversibly inhibit the binding of [(3)H]CGS 21680 in several species varied in the order ratguinea pig > bovinerabbit. In all four species, binding of the A(1)-selective agonist [(3)H]R-N(6)-phenylisopropyladenosine was not diminished by pre-treatment with 2 μM ISC. The kinetics of irreversible inhibition of rat A(2a)-receptors by 2 μM ISC gave a t(1/2) of approximately 3 min. Following partial inactivation, the remaining rat A(2a)-binding sites retained the same K(d) value as in control membranes for saturation by [(3)H]CGS 21680. Thus, ISC appears to be a selective affinity label for A(2a)- versus A(1)-receptors in the brain.

Entities:  

Year:  2004        PMID: 22787287      PMCID: PMC3392128          DOI: 10.1002/ddr.430290407

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  21 in total

1.  RDC8 codes for an adenosine A2 receptor with physiological constitutive activity.

Authors:  C Maenhaut; J Van Sande; F Libert; M Abramowicz; M Parmentier; J J Vanderhaegen; J E Dumont; G Vassart; S Schiffmann
Journal:  Biochem Biophys Res Commun       Date:  1990-12-31       Impact factor: 3.575

2.  Chemical modification and irreversible inhibition of striatal A2a adenosine receptors.

Authors:  K A Jacobson; G L Stiles; X D Ji
Journal:  Mol Pharmacol       Date:  1992-07       Impact factor: 4.436

3.  (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.

Authors:  J Shimada; F Suzuki; H Nonaka; A Ishii; S Ichikawa
Journal:  J Med Chem       Date:  1992-06-12       Impact factor: 7.446

4.  Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells.

Authors:  V Ramkumar; M E Olah; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1991-11       Impact factor: 4.436

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

Authors:  R F Bruns; G H Lu; T A Pugsley
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors.

Authors:  K Niiya; K A Jacobson; S K Silvia; R A Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

8.  Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration.

Authors:  M J Lohse; B Elger; J Lindenborn-Fotinos; K N Klotz; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

Review 9.  Adenosine A1 and A2 receptors: structure--function relationships.

Authors:  P J van Galen; G L Stiles; G Michaels; K A Jacobson
Journal:  Med Res Rev       Date:  1992-09       Impact factor: 12.944

10.  Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors.

Authors:  K A Jacobson; S Barone; U Kammula; G L Stiles
Journal:  J Med Chem       Date:  1989-05       Impact factor: 7.446

View more
  7 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors.

Authors:  A H Li; L Chang; X d Ji; N Melman; K A Jacobson
Journal:  Bioconjug Chem       Date:  1999 Jul-Aug       Impact factor: 4.774

3.  Development of subtype-selective covalent ligands for the adenosine A2B receptor by tuning the reactive group.

Authors:  Bert L H Beerkens; Xuesong Wang; Maria Avgeropoulou; Lisa N Adistia; Jacobus P D van Veldhoven; Willem Jespers; Rongfang Liu; Laura H Heitman; Adriaan P IJzerman; Daan van der Es
Journal:  RSC Med Chem       Date:  2022-06-21

4.  A covalent antagonist for the human adenosine A2A receptor.

Authors:  Xue Yang; Guo Dong; Thomas J M Michiels; Eelke B Lenselink; Laura Heitman; Julien Louvel; Ad P IJzerman
Journal:  Purinergic Signal       Date:  2016-12-03       Impact factor: 3.765

Review 5.  Chemical Probes for the Adenosine Receptors.

Authors:  Stephanie Federico; Lucia Lassiani; Giampiero Spalluto
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-12

Review 6.  Molecular probes for the human adenosine receptors.

Authors:  Xue Yang; Laura H Heitman; Adriaan P IJzerman; Daan van der Es
Journal:  Purinergic Signal       Date:  2020-12-12       Impact factor: 3.765

Review 7.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.